Sigma-Aldrich Corporation Analysis – September 2015 Update $SIAL

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Most Undervalued Companies for the Defensive Investor – August 2015.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Sigma-Aldrich Corporation (SIAL) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): Sigma-Aldrich Corporation is a life science and high technology company. The Company develops, manufactures, purchases and distributes a range of biochemical and organic chemical products, kits and services that are used in scientific research. It manufactures and distributes around 250,000 chemicals, biochemical and other essential products and approximately 46,000 equipment products. Its business unit structure is aligned into three business units: Research, Applied and SAFC Commercial. Its brands include Sigma-Aldrich, Sigma, Aldrich, Fluka, Riedel-de Haen, Supelco, SAFC, SAFC Biosciences, SAFC Hitech, Genosys, Proligo, Pharmorphix, Cerilliant, Vetec, BioReliance and Cell Marque. It offers its products and services to research and applied labs, pharmaceutical companies, universities, commercial laboratories, industrial companies, biotechnology companies and non-profit organizations, among others. It operates in around 37 countries and sells into approximately 160 countries.


To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Here is a free sample valuation pdf, and here is a post detailing what can be found within each individual company’s valuation.


Downloadable PDF version of this valuation:

ModernGraham Valuation of SIAL – September 2015

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $16,715,011,480 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 5.59 Pass
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 75.43% Pass
6. Moderate PEmg Ratio PEmg < 20 34.47 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 5.15 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 5.59 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 0.15 Pass
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

SIAL value Chart September 2015

EPSmg $4.05
MG Growth Estimate 4.33%
MG Value $69.46
Opinion Overvalued
MG Value based on 3% Growth $58.70
MG Value based on 0% Growth $34.41
Market Implied Growth Rate 12.98%
Current Price $139.52
% of Intrinsic Value 200.87%

Sigma-Aldrich Corporation qualifies for the Enterprising Investor but not the more conservative Defensive Investor.  The Defensive Investor is concerned by the high PEmg and PB ratios, while the Enterprising Investor has no initial concerns.  As a result, all value investors following the ModernGraham approach based on Benjamin Graham’s methods should feel comfortable proceeding with further research into the company.

As for a valuation, the company appears to be overvalued after growing its EPSmg (normalized earnings) from $3.14 in 2011 to an estimated $4.05 for 2015.  This level of demonstrated earnings growth does not support the market’s implied estimate of 12.98% annual earnings growth over the next 7-10 years.  As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value below the price.

The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects.  What do you think?  What value would you put on Sigma-Aldrich Corporation (SIAL)?  Where do you see the company going in the future?  Is there a company you like better?  Leave a comment on our Facebook page or mention @ModernGraham on Twitter to discuss.

Stage 3: Information for Further Research

SIAL Charts September 2015

Net Current Asset Value (NCAV) $11.24
Graham Number $50.59
PEmg 34.47
Current Ratio 5.59
PB Ratio 5.15
Dividend Yield 0.66%
Number of Consecutive Years of Dividend Growth 20



Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Total Current Assets $2,369,000,000
Total Current Liabilities $424,000,000
Long-Term Debt $300,000,000
Total Assets $4,306,000,000
Intangible Assets $1,035,000,000
Total Liabilities $998,000,000
Shares Outstanding (Diluted Average) 122,000,000

Earnings Per Share History

Next Fiscal Year Estimate $4.12
Dec14 $4.17
Dec13 $4.06
Dec12 $3.77
Dec11 $3.72
Dec10 $3.12
Dec09 $2.80
Dec08 $2.65
Dec07 $2.34
Dec06 $2.05
Dec05 $1.88
Dec04 $1.67
Dec03 $1.36
Dec02 $0.89
Dec01 $0.94
Dec00 $1.92
Dec99 $0.86
Dec98 $0.82
Dec97 $0.81
Dec96 $0.74
Dec95 $0.66

Earnings Per Share – ModernGraham History

Next Fiscal Year Estimate $4.05
Dec14 $3.93
Dec13 $3.71
Dec12 $3.42
Dec11 $3.14
Dec10 $2.77
Dec09 $2.51
Dec08 $2.28
Dec07 $2.02
Dec06 $1.76
Dec05 $1.52
Dec04 $1.35
Dec03 $1.19
Dec02 $1.10
Dec01 $1.16
Dec00 $1.19
Dec99 $0.81

Recommended Reading:

Other ModernGraham posts about the company

Sigma-Aldrich Corporation Analysis – June 2015 Update $SIAL
18 Companies in the Spotlight This Week – 3/15/15
Sigma-Aldrich Corporation Quarterly Valuation – March 2015 $SIAL
32 Companies in the Spotlight This Week – 12/6/14
Sigma-Aldrich Corporation Quarterly Valuation – December 2014 $SIAL

Other ModernGraham posts about related companies

FMC Corporation Analysis – September 2015 Update $FMC
Eastman Chemical Company Analysis – September 2015 Update $EMN
Ashland Inc. Analysis – Initial Coverage $ASH
The Best Companies of the Chemicals Industry – August 2015
LyondellBasell Industries Analysis – August 2015 Update $LYB
Albemarle Corporation Analysis – Initial Coverage $ALB
E I Du Pont de Nemours & Company Analysis – August 2015 Update $DD
Dow Chemical Analysis – July 2015 Update $DOW
Sigma-Aldrich Corporation Analysis – June 2015 Update $SIAL
Eastman Chemical Company Analysis – June 2015 Quarterly Update $EMN


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.